Navigation Links
SFU researchers help discover new HIV vaccine-related tool
Date:2/28/2012

A new discovery involving two Simon Fraser University scientists could lead to a little known and benign bacterium becoming a vital new tool in the development of a vaccine against human immunodeficiency virus (HIV).

Ralph Pantophlet, a Faculty of Health Sciences assistant professor, and Kate Auyeung, his senior research assistant and lab manager at SFU, and scientists in Italy have made a breakthrough discovery about Rhizobium radiobacter.

The journal Chemistry & Biology has just published their research in its Feb. 24 issue.

The research team has discovered this harmless bacterium has on its surface sugar molecules that resemble those on the surface of HIV.

This resemblance gives scientists a basis for developing a preventative vaccine, putting our immune system on guard against HIV.

HIV's sugar molecules act as a cloaking device, preventing our immune system from detecting the virus until it has created several variant generations of itself.

By the time our immune system's recognition has kicked in, weeks have elapsed, and HIV is several steps ahead of our body's efforts to eliminate it.

Pantophlet and his colleagues believe the sugar molecules on Rhizobium radiobacter could be used to trigger our immune system to immediately recognize those on HIV, prompting more immediate awareness of the virus' invasion.

"The irony of our discovery is not lost on us," says Pantophlet. "We've found that a harmless species of a bacteria family that can cause tumours in the roots of legume plants could become a vital tool in the fight against one of the deadliest infectious diseases."

Before Rhizobium radiobacter can become the basis of an anti-HIV vaccine, the scientists need to find a protein to which they can attach the bacterium's sugar molecules. The protein is needed to properly trigger our immune system's development of antibodies to the sugar molecules. Such antibodies would then recognize and target HIV's sugar molecules because they resemble those on the bacterium.

This method of triggering antibodies' development has led to the invention of successful sugar-based vaccines against diseases such as meningitis and childhood pneumonia.

"Two known proteins, tetanus toxoid and CRM197, a nontoxic recombinant variant of diphtheria toxin, are commonly used to develop these kinds of vaccines," explains Pantophlet. "So a lot of the groundwork is there for us to be able to have a vaccine that could be tested in a lab first and then in clinical trials later on."

Pantophlet and his colleagues are seeking grant funding from the Canadian Institutes for Health Research to continue their research.

If they get the grant, they hope to attach Rhizobium radiobacter's sugar molecules to a protein and create vaccine candidates for testing within the next one to two years.


'/>"/>
Contact: Carol Thorbes (SFUPAMR)
cthorbes@sfu.ca
778-782-3035
Simon Fraser University
Source:Eurekalert

Related biology news :

1. Notre Dame researchers are providing insights into elephant behavior and conservation issues
2. Researchers develop worlds first biodegradable joint implant
3. Researchers identify novel pathway responsible for infection of a common STD pathogen
4. Researchers discover how vitamin D inhibits inflammation
5. Purdue researchers reveal role of protein mutation in Parkinsons disease
6. UVic researchers among presenters at global science conference
7. Researchers develop better control for DNA-based computations
8. Researchers warn nanoparticles in food, vitamins could harm human health
9. Worlds top technology researchers coming to Queens for TEI 2012
10. Researchers make living model of brain tumor
11. MDC researchers reveal molecular mechanism underlying severe anomalies of the forebrain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: